• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » ACC 2014: Conflicts in renal denervation, competition in valves

ACC 2014: Conflicts in renal denervation, competition in valves

April 3, 2014 By Arezu Sarvestani

fired/hired

The American College of Cardiology’s annual Scientific Sessions are regularly a source of controversy and competition, but medtech titan Medtronic’s (NYSE:MDT) highly anticipated renal denervation study results may have been the most confounding.

Seemingly conflicting reports from Medtronic’s SYMPLICITY HTN-3 clinical trial and SYMPLICITY registry alternately painted renal denervation as either an ineffective treatment or a valuable option for patients with drug-resistant hypertension.

In results from the HTN-3 trial renal denervation barely lowered blood pressure compared with a sham procedure, falling short of endpoints for efficacy. The therapy resulted in a 2.39 mm Hg greater reduction in blood pressure at 6 months than the sham arm, failing to achieve statistical significance. Ambulatory readings taken over a 24-hour period showed a 1.96 mm Hg difference compared with the sham control arm.

In registry outcomes, however, data from more than 750 patients showed an 11.9 mm Hg reduction in blood pressure at 6 months. Among patients with a baseline at or above 160 mm Hg, average reduction was 21.4 mm Hg Ambulatory readings, which included about 400 patients, showed a 7.9 mm Hg reduction in blood pressure.

Since there was no placebo control and no blinding, it’s difficult to compare to the registry outcomes with the clinical trial, which was the most rigorous study to date to examine renal denervation in treatment of drug-resistant hypertension.

Some, including registry results presenter Dr. Michael Bohm, argued that the studies are too different to be considered together. The data is complementary, but not parallel, Bohm told Medscape.

Some physicians have said it’s too early to make the call on renal denervation, but others have been less optimistic. One study insider said anonymously earlier this year that renal denervation is "highly unlikely" to make the grade for treating hypertension.

Others remain optimistic that renal denervation can play a role in patient treatment. Cardiologist Dr. Darrel Francis, who correctly predicted that the HTN-3 outcomes would fail to excite, has defended the technology as a good option for the right patients.

"Symplicity 3 teaches us that the history of denervation needs to be wiped, and started afresh, relying only on randomized blinded data. At least now the unknown unknowns are becoming known unknowns," Francis told MassDevice.com. "It is a huge relief that at last there is a trial reported that has the design features that have for the last 2 decades been known to be essential for trials of intervention for hypertension: randomization and blinding.

Competition in valves

Medtech’s giants highlighted the latest on their transcatheter valve implantation systems, with Medtronic, Edwards Lifesciences (NYSE:EW) and Boston Scientific (NYSE:BSX) both touting strong performance data on their valves.

Medtronic touted 1-year data on its newer Melody transcatheter pulmonary valve, saying the device performed well in patients at 1 year of follow-up. The technology has FDA Humanitarian Device Exemption and has been available since 2010. The study included patients with ages ranging from 5 to 45, with an average age of 20 years old, according to Reuters.*

Medtronic also made progress on its higher-profile CoreValve transcatheter aortic valve, saying that the company won approval to skip an FDA advisory panel hearing on treating high-risk patients.

Edwards made its own TAVI announcement, saying that its Sapien XT system bested CoreValve in a small head-to-head study. Sapien produced higher rates of overall "device success" in the 241-patient CHOICE study, Edwards said.

Not one to be left out, Boston Scientific provided a 3-month study update on its Lotus TAVI system, saying that the technology resulted in low rates of leakage. There were no reports of severe leakage at 90 days and 85.4% freedom from any kind of leakage, according to independent core lab assessments, Boston Scientific said.

Valve leakage is a major concern in TAVI devices, especially in the older generations of the technology. Leakage in the valve is an important indicator of mortality.

More MassDevice.com coverage of ACC 2014.

Updated April 3, 2014. This article mistakenly stated that the Melody valve won HDE in 2012; the exemption was granted in 2010.

Filed Under: News Well, Replacement Heart Valves Tagged With: ACC 2014, American College of Cardiology Conference (ACC), Boston Scientific, Clinical Trials, Conference coverage, Edwards Lifesciences, Hypertension, Renal

In case you missed it

  • Avenda wins FDA IDE nod for AI-enabled prostate cancer therapy
  • Nuvasive chief commercial officer Massimo Calafiore is stepping down
  • Preparing your medical device company for challenging market conditions
  • Dentsply Sirona replaces chief accounting officer amid internal investigation
  • Haemonetics stock rises on Street-beating Q1, raised guidance
  • Surgalign settles on OEM business sale, posts Q2 earnings miss
  • Alcon lowers its 2022 forecast amid strong dollar
  • Masimo beats Street in Q2 as healthcare business catches up
  • Senseonics stock is up as it sticks by revenue guidance
  • Butterfly Network asks judge to dismiss Fujifilm Sonosite IP suit
  • Stereotaxis stock down amid cloudy outlook
  • The 10 largest orthopedic device companies in the world
  • BD, Labcorp collaborate on flow cytometry-based diagnostics
  • NeuroOne submits special FDA 510(k) application for Evo sEEG electrode
  • Si-Bone grows sales 15% in Q2
  • FDA approves second IDE study for CereVasc eShunt
  • Nuwellis posts Q2 sales beat

RSS From Medical Design & Outsourcing

  • Boston Scientific whistleblower launches corruption investigation
    Boston Scientific (NYSE:BSX) is investigating claims that the company violated the U.S. Foreign Corrupt Practices Act in Vietnam. Marlborough, Massachusetts–based Boston Scientific disclosed receipt of a whistleblower’s allegations in its latest filing with the Securities and Exchange Commission. “In March 2022, the company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam.… […]
  • 5 essential leadership lessons from Cathy Burzik for medtech’s next generation of women leaders
    Cathy Burzik, a seasoned senior executive in the healthcare industry, has successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses. Cathy Burzik, CFB Interests (as told to MedExecWomen co-founder Maria Shepherd) One key to being a successful women leader in MedTech: “Play nice, but play to win.” Cathy Burzik, who received a… […]
  • Stratasys plans to buy Covestro’s additive manufacturing business
    Stratasys (Nasdaq:SSYS) said today that it has a deal to purchase the additive manufacturing materials business of Covestro. The deal includes R&D facilities and activities, global development and sales teams across Europe, the U.S. and China, a portfolio of approximately 60 additive manufacturing materials, and hundreds of patents and patents pending, Stratasys said in a… […]
  • New implant design prevents scar tissue without drugs, MIT says
    Mechanically inflating and deflating an implantable device for 10 minutes a day prevents immune cells from building the scar tissue that has been a major obstacle for artificial pancreas researchers. That’s according to new findings from a team of MIT engineers who built mechanical deflection into a two-chambered, soft polyurethane device tested on mice. By… […]
  • Blue Spark’s TempTraq catches fevers faster. Fever prediction is next.
    Blue Spark Technologies developed the first wireless continuous temperature monitor patch, TempTraq, to enable faster fever detection than standard manual readings every four hours. Westlake, Ohio-based Blue Spark is now looking at fever prediction rather than just detecting them. The R&D team is working on developing an AI neural network model built on the company’s… […]
  • Harvard researchers plan to sell at-home, PCR-grade COVID testing system
    The Harvard University researchers who developed an ultrasensitive, PCR-grade nucleic acid detection technology plan to commercialize it as a portable COVID-19 test. Harvard Medical School professor Peng Yin, who also leads the Wyss Institute for Biologically Inspired Engineering’s Molecular Robotics Initiative, founded 3EO Health to sell the device. “In order to optimize the value of… […]
  • FDA reports sterilization challenge progress as EPA takes aim at EtO emissions
    The FDA offered an update on its efforts to make medical device sterilization safer as the EPA identified 23 U.S. facilities where use of ethylene oxide (EtO) presents a risk to communities. The FDA said it is similarly concerned about unsafe EtO emissions and highlighted work with the medical device industry to reduce EtO usage… […]
  • AdvaMed defends EtO facilities on EPA’s cancer risk list
    The Advanced Medical Technology Association (AdvaMed) today reacted to the EPA’s listing of commercial sterilization facilities causing elevated risks of cancer with a defense of the facilities and a call for more research. AdvaMed CEO and President Scott Whitaker said all of the listed facilities are in compliance with regulations and warned against closures. “The… […]
  • EPA flags high-cancer-risk EtO sterilization facilities across the country
    The EPA today identified nearly two dozen U.S. cities where commercial sterilizers using ethylene oxide (EtO) contribute to an elevated cancer risk for residents of surrounding communities. EtO is used on about 20 billion medical devices each year — or about half of all sterile medical devices —  and in some cases it’s the only… […]
  • New method of cardiac ablation used in first in-human trial for ventricular tachycardia
    A new cardiac ablation technique for patients with ventricular tachycardia (VT) has been used in its first in-human multicenter trial involving Mayo Clinic. The new process — needle ablation using in-catheter, heated, saline-enhanced, radio frequency (SERF) energy — creates lesion scars inside the heart muscle where life-threatening arrhythmias cause VT, Mayo Clinic said. Injecting heated saline… […]
  • AdvaMed pushes CMS for proposed TCET pathway rule this year
    The Advanced Medical Technology Association (AdvaMed) is asking the Centers for Medicare & Medicaid Services (CMS) to move fast on a new way to guarantee reimbursement for new medtech innovations. CMS repealed the Medicare Coverage of Innovative Technology (MCIT) program last year but promised to explore other options to improve the coverage process for access… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

August 5, 2022
DTW Medtronic's Greg Smith lays out supply chain strategies
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy